Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
- $150,000
- Not stated
- Dec 30, 2024
Official announcement on nih_guide+grants_gov · opens the funder's page. Always confirm dates there.
Summary
The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). […]
Other topics in this solicitation
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
$250k
Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional)
Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
$100k
The rest of this announcement — free with an account
- The full announcement text, not the first two sentences
- All 3 review criteria reviewers score this against, extracted from this announcement
- Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- What similar funded projects received, from 219,000 past awards
More from National Institutes of Health
NIH Director’s Early Independence Award (DP5 Clinical Trial Optional)
$350k
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
$250k
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
$350k